Despite being a major health problem, the magnitude of viral infections in India and their effects on transplant recipients have not been studied thoroughly. Most studies in the past have used antigenemia determined by an enzyme immunoassay (EIA), an indirect method, to investigate the viral infections. An EIA moreover has inherent intra-and inter-laboratory variability in the results thereby affecting comparability and in turn clinical practice. Robust and more sensitive screening or diagnostic measure like actual viral load using quantitative real time PCR (qRT-PCR) has an edge over serological methods and is now considered to be a method of choice for identifying viral infection. The qRT-PCR not only gives a better idea about impact of viral infections after transplantation but may also help in their timely detection and management of graft recipients thereby improving the outcome.
Also, little is known about influence of immunosuppressive drugs or induction therapy on risk of infection or reactivation of virus and their association with rejection episodes. Few studies utilizing serological assays for defining viral infections have been recently published but there is need to redefine the actual incidence of viral infections and their impact on transplant outcome. Studies on quantitative analysis of CMV and EBV coinfection in patients of renal transplant are meager and further validation of earlier similar studies is needed. 6, 7 We therefore aimed to analyze the role of two most common viral infections, the CMV and EBV in renal transplant outcome, by quantification of EBV and CMV DNAemia in peripheral blood of renal transplant recipients in different time intervals using qRT-PCR.
Methods
In this prospective longitudinal observational study, conducted in the departments of Renal Transplant Surgery and department of Immunopathology, a total of 50 patients undergoing renal transplantation were included and followed up for a duration of 6 months after renal transplant. A written informed consent was obtained from the patients as per guidelines and the study was approved by the Institute's Ethics Committee.
Clinical details and demographic data were collected. Baseline investigations were carried out and tests for checking CMV, hepatitis B, C and human immunodeficiency virus (HIV) seropositivity were done in both patients and the donors at the time of preparation for transplantation. Immunosuppressive medications in transplant recipients were started 24 h prior to transplantation consisting of a combination of either tacrolimus or cyclosporine A with either mycophenolate mofetil (MMF) or azathioprine (AZT). In addition, unrelated and spousal transplants were given IL-2 receptor antagonist (Basiliximab 20 mg, 2 doses) or antithymocyte globulin (ATG; Thymoglobulin 3-3.5 mg/kg over 3 days) as an inducing agent. After achieving a stable graft function, as determined by daily urine output, serial creatinine measurements and free of any evidence of active infection, patients were discharged from the hospital. Recipients were called up for weekly follow-up on outpatient basis till the end of third month after transplantation and thereafter at the end of 6 months. Data regarding graft dysfunction and immunosuppression were collected at the time of discharge and during follow-up intervals.
Monitoring for CMV by qRT-PCR was done after 1, 2, 3 and 6 months and for EBV at 1, 3, and 6 months after renal transplantation. Additional tests for CMV and EBV by qRT-PCR were done if patient presented with symptoms suggestive of viral infection e.g. fever, flu like symptoms, decreased blood counts, hepatitis or other signs of organ specific manifestation and graft dysfunction. None of the patients received any primary prophylaxis for CMV or EBV after transplantation.
CMV and EBV viral load were measured (in 50 cases and 36 cases respectively) by qRT-PCR system (LightCycler LC480 Real Time PCR system, Roche applied Science, USA) using TaqMan probe chemistry for absolute quantification. In brief, the genomic DNA was extracted from 250 ml of EDTA blood using AxyPrep DNA extraction kit (Axygen Biosciences, USA) and the protocol was followed as per manufacturer's instructions. The primers for CMV were designed from the CMV glycoprotein B (gB) gene (strains) and for EBV from nonglycosylated membrane protein BNRF1 p143 ( Table 1 ).
The genomic DNA thereafter was amplified using primer-probe and mastermix (Roche Diagnostics GmbH, Roche Applied Science, Germany) containing Taq DNA polymerase, reaction buffer, and deoxynucleotide triphosphates (dNTPs). The reaction was initially denatured for 5 min at temperature of 94 8C. The annealing and extension temperatures were 58 8C and 72 8C and number of cycles was 40. The exact number of copies/ml blood was calculated by extrapolation from the standard curve obtained using commercially available standards (CMV strain AD169). Serial dilutions were run on LightCycler and a linear assay was obtained across 6 orders of magnitude, sensitive for 10 1 -10 8 copies/ml, and multiplied by the multiplication factor of 600 (lowest range of detection of number of copies/ml).
After detection of viral infection, standard protocols for the management of CMV/EBV infection in transplant recipients were followed. Initially patients were treated with 5 mg/kg of Ganciclovir with concurrent reduction in immunosuppression till viral load was negative or for a minimum of 3 weeks. This was followed by 900 mg of Valganciclovir prophylaxis for up to 3 months.
Statistical analysis
For time fixed variables, continuous data were assessed using Student t test or Mann-Whitney U test depending on data distribution. Receiver operating characteristic (ROC) plot analysis was used to determine a cutoff of significant viral load. Descriptive statistics for population profiles, frequency and percentage for categorical data and mean and standard deviation for continuous data were used.
Results

General characteristics of study group
Among the patients there were 43 males (86%) and 7 females (14%). Mean age was 35.1 AE 10.9 years (range 12-58 years). Chronic glomerulonephritis was most common primary disease (42/50; 84%) followed by IgA nephropathy and adult polycystic kidney disease (3/50; 6% each) and diabetic nephropathy (2/50; 4%). Twenty one patients (42%) had living, related donor; 23 (46%) had living unrelated donors and deceased donors were used for another 6 (12%) patients. Among the donors, 18 were males (36%) and 32 females (63%). Mean age was 40.7 AE 12.7 years. All except one were serologically negative for hepatitis B and C. All the patients as well as donors sera were nonreactive for HIV. Pre transplantation CMV seroprevalence in the patients was 96% and 98% among the donors (donor + /recipient + 48 patients, donor + /recipient À and donor À /recipient + 1 patient each) ( Table 2) . Table 1 Sequence details of primers used for CMV and EBV DNA quantification.
Virus
Target gene Specific forward and reverse primers
Induction therapy was given to 23 (46%) patients of which 19 (38%) received ATG and remaining 4 (8%) received induction with Simulect (Basiliximab, IL-2 receptor antagonist). All recipients were given triple immunosuppression therapy. During follow-up 5 (10%) patients were switched to Sirolimus based regime for various indications.
Incidence of CMV and EBV infection
A total of 44% (22/50) of patients were found to have viral infections. Incidence of CMV and EBV infection in patients was 34% and 20% respectively. CMV and EBV co-infection was seen in 5 (10%) patients. Asymptomatic CMV infection (presence of CMV DNA without any clinical signs and symptoms) was noted in 6 (35%) patients, while 11 (22%) patients had symptomatic CMV infection. None of the patients with EBV viremia showed and evidence of EBV disease i.e. Post Transplant Lymphoproliferative Disorder (PTLD) till last follow up.
Out of 22 patients with viral infection, 19 (86%) were males and 3 (14%) females with mean age of 36.1 years. Pre-transplant CMV seropositivity in these infected recipients was D + /R + in 16 (94%) and D + /R À in 1 (6%). Twelve (54%) of these patients received ATG induction and 3 (14%) patients were given Simulect as induction therapy. Six (27%) patients did not receive any induction therapy. Forty seven patients (94%) received Tacrolimus based triple immunosuppressant therapy. 
Disease onset
Viral load
Asymptomatic patients had viral load ranging from 13,565 to 8,940,000 copies/ml with mean value of 81,300 copies/ml (Table 3) .
Symptomatic viral load was 600,000 copies/ml but the p-value of viral loads between two groups was insignificant (p = 0.801). Using ROC curves cutoff value of blood CMV viral load in prediction of symptomatic CMV infection was 141,800 copies/ml with maximum sensitivity of 81.8% and specificity of 67.4%. 
Clinical features
Majority of the patients (44%) had raised creatinine (defined as >20% increase from baseline) as their initial presenting feature. Symptoms related to renal, gastrointestinal, respiratory and hematological system were most common (Fig. 2) . One (6%) patient with CMV and EBV co-infection had antibody mediated rejection for which he received pulse methylprednisolone and ATG following which he developed CMV infection.
Coinfection in CMV and EBV patients
Overall infection rate was 41%. Among the infected patients 3 (43%) had urinary tract infection, 2 (27%) had tuberculosis (1 case of pulmonary and in other involving cervical lymphnodes) and other 2 (27%) patients had fungal infection (1 patient had esophageal candidiasis and 1 had phaeohyphomycosis of foot).
Treatment for CMV and EBV infection
Among 17 patients with CMV infection, those who were symptomatic 4 (22%) and 3 (17.6%) asymptomatic were given oral Valganciclovir or intravenous Ganciclovir for 21 days followed by oral Valganciclovir for 3 months after resolution of CMV infection. During treatment, 3 patients who developed leucopenia were given adjusted dose of MMF. One patient developed persistent leucopenia requiring discontinuation of Ganciclovir.
Risk factors and impact on survival
Only ATG induction was found to be significant (p value 0.02, odds ratio 6.05, 95% CI: 1.598-22). The mean baseline serum creatinine of the patients was 1.3 AE 0.5. Seven patients (41%) presented with graft dysfunction (increased creatinine) at the time of presentation with a mean creatinine value of 2.3 AE 0.3. All these were treated for CMV infection. One patient had renal artery stenosis with persistent high creatinine. Post treatment creatinine levels reached baseline level in remaining 6 patients. Graft survival was 100% in both the infections.
Discussion
The immune compromised state as a result of immunosuppressive therapy given after renal transplant predisposes the patients to several microbial infections of which viral infections (e.g. CMV, EBV, HBV, HTLV-1, and HSV-2) are the most common. Our study analyzed the incidence, prevalence and risk factors of CMV and EBV infection and disease in renal transplant patients in post transplant period.
In the present study, antibody prevalence for CMV among donors was 98% and among recipients, it was 96%. Sakhuja et al. have reported similar results in Indian population with antibody prevalence ranging from 85 to 100%. 8 Another Indian study from CMC Vellore showed that more than 90% of the donors and recipients tested were infected with CMV. 9 CMV infection in the post transplant period in Indian transplant recipients is therefore common and is mostly due to reactivation of the latent infection in the recipients. In western literature the CMV antibody prevalence is variable. Skar et al. reported a prevalence rate of 76% among Norwegian kidney transplant recipients and their living donors. 10 Terasaki et al. observed a substantial difference in CMV positivity in different areas of the USA, ranging from 36% in Ohio to 65% in Washington. 11 Khameneh et al. in a study on 96 Iranian renal transplant recipients noted 34.3% seropositivity for CMV and confirmed CMV infection in about 50% of seropositive cases by conventional PCR study. 12 Data on natural course of EBV infection after solid-organ transplantation is very scarce. In a single study by Bamoulid et al. EBV reactivation was seen in 40% of patients within first year of renal transplant. 13 In our study asymptomatic EBV viremia was found in 20% of patients with high viral load in first 3 months post transplant. In contrast to above study in which EBV infection was associated with the occurrence of opportunistic infections and a higher risk of graft loss, in the present study no adverse effects on graft were noticed till the time of follow up.
Incidence of CMV infection in post renal transplant patients has been reported to vary from 8-32%. Sagedal et al. reported an incidence of infections in seropositive recipients irrespective of donor status ranging from 25 to 40% similar to current study. 14 CMV disease was seen in 22% of the patients in our study. Rao et al. have reported 30% incidence of CMV disease in CMC Vellore comparable with our study. 15 Mishra et al. from Ahmedabad have also reported an incidence of 22%. 16 Compared to present study, an incidence of EBV viremia reported in similar studies is nearly 40% both in pediatric and adult patients. 13, 17 In our study, all EBV and 94.2% of the CMV infection occurred during first 3 months post transplant period. Sixty percent of EBV and 23.5% CMV infection occurred during 1st post op month and 40% EBV and 70.6% CMV infection occurred during 2nd and 3rd post operative months which is consistent with the previous studies. A recent study by Coredro et al. has also concluded that the highest incidence of infection occurs during first 3 post operative months. 18 Kumar et al. published similar finding that the period with highest risk of contracting CMV infection is first 100 post operative days. 19 The reason for this high rate of infection is due to high level of immunosuppression during this period.
In our study, the most common clinical symptom at presentation was diarrhea (17.6%) followed by fever and malaise (12% each). The most common clinical presentation of CMV disease is fever, malaise, anorexia and myalgia as reported in various studies. Rubin et al. opined that various infectious disease syndromes attributable to CMV infection have fever as the most common manifestation along with other constitutional symptoms such as malaise, anorexia and myalgia. 20 Coredro et al. also reported similar results in a recent study. 18 Most common laboratory abnormality after infection was increased creatinine (41%) followed by leucopenia (23.5%) and neutropenia (12%). Pour-Reza-Gholi et al. showed that the most common laboratory abnormality in these patients was raised serum creatinine and reduced cell counts. 21 A prospective study by Kute et al. from Ahmedabad also had similar finding. 22 Majority (6/ 7) of our patients with raised creatinine recovered their graft function after treatment with intravenous Ganciclovir. One patient had persistent raised levels of creatinine and later was diagnosed to have renal artery stenosis. CMV has been implicated in the pathogenesis of transplant renal artery stenosis. Pouria et al. have shown role of CMV infection on transplant renal artery stenosis in their study. 23 There was no graft loss or mortality in our study group. Thus early diagnosis and adequate treatment of viral infection can prevent graft failure.
Though, viral load measured with CMV PCR analysis in asymptomatic patients was less than those with symptomatic infection, the difference in copy numbers was not statistically significant. In predicting symptomatic CMV infection the viral load of 141,800 copies/ml had maximum sensitivity of 81.8% and specificity of 67.37%.
Forty three percent of patients in this study had other infections as well in addition to CMV and EBV of which urinary tract infection was commonest (43%). Apart from bacterial infections, fungal and tubercular infections (27% each) were also seen and treated with antifungal and antitubercular drugs respectively. A similar study by Kute et al. also reported an overall 53% co-infection rate and the commonest one was UTI occurring in 34% of infected patients. 22 Patients with CMV and/or EBV infection are therefore at high risk of developing bacterial and fungal infections.
Our study showed significant association between ATG induction and incidence of CMV and EBV infection (p value = 0.02, odds ratio = 6.0595, CI = 1.598-22.90). Viral load was higher and the duration of viremia was longer in patients who received ATG. The findings are consistent with results in a study by Kanter et al. who claimed induction therapy with ATG and maintenance immunosuppression with cyclosporine to be major risk factors for CMV disease in recipients more than 55 years of age. 24 CMV disease has been shown to be a potential risk factor for graft dysfunction and acute allograft rejection in renal transplant recipients. 14, 18, 21 In our study among the infected patients 7 had graft dysfunction in the form of elevated creatinine baseline level after treatment. As previously mentioned 6 patients' serum creatinine level reached baseline. None of the patient developed rejection after the treatment of CMV disease within the study period. Since this study had small strength of patients and follow up was only for 6 months (the period when there is maximum immunosuppression), it may be the reason why graft loss did not occur in this period.
Conclusion
The study confirmed a high prevalence of exposure to CMV and EBV in Indian population. High CMV antibody prevalence in our population suggests reactivation of the latent infection in the recipients is responsible for CMV infection in post transplant period. ATG induction is a definitive risk factor for CMV/EBV infection in post operative period. Symptomatic infection is common during the first 3 months after transplant and diarrhea may be one of the usual presenting features. Due to financial limitations we could not extend the periodic monitoring of these infections it is suggested that these patients particularly those induced with ATG should be regularly followed up with qRT-PCR may be for at least 2 years. More over these patients are at high risk for developing co-infections and hence they should also be monitored for the presence of other infections.
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